Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 5
1959 11
1960 10
1961 11
1962 14
1963 25
1964 22
1965 13
1966 19
1967 23
1968 39
1969 22
1970 18
1971 27
1972 11
1973 18
1974 16
1975 10
1976 13
1977 11
1978 8
1979 13
1980 9
1981 11
1982 10
1983 4
1984 8
1985 9
1986 3
1987 6
1988 3
1989 6
1990 4
1992 5
1993 6
1994 6
1995 1
1996 4
1997 6
1998 13
1999 8
2000 11
2001 9
2002 15
2003 13
2004 12
2005 16
2006 17
2007 13
2008 15
2009 15
2010 16
2011 23
2012 26
2013 31
2014 27
2015 34
2016 54
2017 54
2018 84
2019 71
2020 142
2021 212
2022 347
2023 432
2024 103

Text availability

Article attribute

Article type

Publication date

Search Results

2,025 results

Results by year

Filters applied: . Clear all
Page 1
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. Lowe H, et al. Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948. Molecules. 2021. PMID: 34063505 Free PMC article. Review.
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment …
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as …
DARK Classics in Chemical Neuroscience: Psilocybin.
Geiger HA, Wurst MG, Daniels RN. Geiger HA, et al. ACS Chem Neurosci. 2018 Oct 17;9(10):2438-2447. doi: 10.1021/acschemneuro.8b00186. Epub 2018 Jul 16. ACS Chem Neurosci. 2018. PMID: 29956917 Review.
In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psilocin which are found in psilocybe mushrooms. Psilocybin was marketed by Sandoz as Indocybin for basic psychopharmacological and therape …
In the late 1950s Albert Hofmann, of Sandoz Laboratories, identified and synthesized the psychoactive compounds psilocybin and psiloc …
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM. Passie T, et al. Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937. Addict Biol. 2002. PMID: 14578010 Review.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. ...Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until rece
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed world
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
Dinis-Oliveira RJ. Dinis-Oliveira RJ. Drug Metab Rev. 2017 Feb;49(1):84-91. doi: 10.1080/03602532.2016.1278228. Epub 2017 Jan 31. Drug Metab Rev. 2017. PMID: 28074670 Review.
Psilocybin and psilocin are controlled substances in many countries. ...Psilocybin is primarily a pro-drug that is dephosphorylated by alkaline phosphatase to active metabolite psilocin. ...
Psilocybin and psilocin are controlled substances in many countries. ...Psilocybin is primarily a pro-drug that is dephosphory
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.
Ling S, Ceban F, Lui LMW, Lee Y, Teopiz KM, Rodrigues NB, Lipsitz O, Gill H, Subramaniapillai M, Mansur RB, Lin K, Ho R, Rosenblat JD, Castle D, McIntyre RS. Ling S, et al. CNS Drugs. 2022 Jan;36(1):17-30. doi: 10.1007/s40263-021-00877-y. Epub 2021 Nov 17. CNS Drugs. 2022. PMID: 34791625 Review.
Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. ...The aim of this review is to synthesize the current understanding of the receptor pharmacology and neuronal mechanisms underlying the psych …
Preliminary studies with psilocybin have shown therapeutic promise across diverse populations including major depressive disorder. .. …
Psilocybin for Trauma-Related Disorders.
Khan AJ, Bradley E, O'Donovan A, Woolley J. Khan AJ, et al. Curr Top Behav Neurosci. 2022;56:319-332. doi: 10.1007/7854_2022_366. Curr Top Behav Neurosci. 2022. PMID: 35711024 Review.
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. .. …
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, Finan PH, Griffiths RR. Davis AK, et al. JAMA Psychiatry. 2021 May 1;78(5):481-489. doi: 10.1001/jamapsychiatry.2020.3285. JAMA Psychiatry. 2021. PMID: 33146667 Free PMC article. Clinical Trial.
IMPORTANCE: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects …
IMPORTANCE: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adh …
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Gukasyan N, et al. J Psychopharmacol. 2022 Feb;36(2):151-158. doi: 10.1177/02698811211073759. J Psychopharmacol. 2022. PMID: 35166158 Free PMC article. Clinical Trial.
AIMS: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MDD who received psilocybin. ...There were no serious adverse events judged to be related to psilocybin in the long-term follow- …
AIMS: This study sought to examine the efficacy and safety of psilocybin through 12 months in participants with moderate to severe MD …
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Carhart-Harris RL, et al. Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17. Lancet Psychiatry. 2016. PMID: 27210031 Free article. Clinical Trial.
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. ...This trial is registered with ISRCTN, number I …
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored fo …
Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
Ehrmann K, Allen JJB, Moreno FA. Ehrmann K, et al. Curr Top Behav Neurosci. 2022;56:247-259. doi: 10.1007/7854_2021_279. Curr Top Behav Neurosci. 2022. PMID: 34784024 Review.
We briefly describe currently available treatments, mechanisms of action, and efficacy limitations, as preamble to the potential use of psilocybin and perhaps similar compounds in the treatment of OCD and related conditions. Although much is reviewed throughout this book a …
We briefly describe currently available treatments, mechanisms of action, and efficacy limitations, as preamble to the potential use of p
2,025 results